COMPLEX SCIENCE, CLEAR DIRECTION
INTEGRATED SCIENTIFIC AND REGULATORY STRATEGY FOR COMPLEX DRUG DEVELOPMENT PROGRAMS
DAWN SCIENTIFIC
Dawn Scientific, led by Melissa Dawn, Principal Scientist and Managing Director, provides integrated scientific and regulatory strategy for complex drug development programs from API development through regulatory approval. The practice bridges the gap between scientific innovation and regulatory execution in emerging therapeutic areas.
END-TO-END INTEGRATION
From synthetic route selection, formulation development, and process chemistry through clinical design, regulatory submissions, and approval, we provide technical execution and strategic guidance across every development phase. Specialized expertise in psychedelic therapeutics, neuroplastogens, controlled substances, and novel molecular programs.
WORLDWIDE INSIGHT
Regulatory requirements differ across major markets. We design programs to work across FDA, EMA, Health Canada, PMDA, TGA, and regional authorities from the start, preventing late-stage delays and costly modifications when entering new markets.
SCIENCE
Science that defines boundaries. Insight that expands them.
NON-HALLUCINOGENIC NEUROPLASTOGENS
HIGH-SCRUTINY NEUROACTIVE
MOLECULES
BIOLOGICALLY
DERIVED &
BIOSYNTHETIC
MOLECULES
PSYCHEDELIC-CLASS
COMPOUNDS
PRODRUGS &
METABOLIC
PRECURSORS
STRUCTURALLY
COMPLEX NATURAL PRODUCTS
FIRST-IN-CLASS NEUROTHERAPEUTICS
EXTRACT-DERIVED APIs
STRUCTURALLY
MODIFIED ANALOGS
SERVICES
From molecule to approval, across every development phase and regulatory market.
CLIENTS
The clients who engage Dawn Scientific share a specific profile. Complex science, consequential decisions, and programs where the right expertise materially changes outcomes.
Early-stage companies establishing the scientific and regulatory foundation their programs require.
Clinical-stage programs navigating first-in-human development.
Established biopharma expanding into psychedelic-class compounds, neuroplastogens, or novel molecules.
API manufacturers developing synthetic, naturally derived, or biosynthetic compounds that are complex, novel, or both.
International organizations entering unfamiliar regulatory markets beyond their borders.
Law firms and legal teams retaining scientific and regulatory expertise outside their practice.
HOW WE WORK
Principal-led engagements supported by specialist expertise. One point of accountability across every development phase.
DIRECT PRINCIPAL ENGAGEMENT
Every client engagement is led directly by the Principal Scientist and Managing Director. Strategic decisions, client communication, and program direction come from principal-level expertise throughout, ensuring accountability and continuity.
SPECIALIST NETWORK
Specialist expertise is engaged for deep technical work when needed, expanding capabilities across chemistry, manufacturing, preclinical, clinical, and regulatory domains while maintaining strategic coherence and accountability.
STRATEGIC INVOLVEMENT
Active participation in regulatory strategy, technical problem-solving, and critical development decisions rather than advisory recommendations alone. Hands-on engagement when principal-level judgment materially impacts program outcomes.
WHEN TO ENGAGE
Complex science. Critical development moments.
WHEN REGULATORY OR CLASSIFICATION IS UNCLEAR
Your program involves unconventional molecules, controlled substances, or novel mechanisms where classification, scheduling, or regulatory expectations are not clearly defined. Assumptions made early can introduce significant risk if they do not align with regulatory interpretation.
WHEN SCIENCE MAY NOT TRANSLATE INTO A VIABLE PRODUCT
Promising data or novel sources must be translated into a development-ready API. Challenges in process, purity, scalability, or formulation can undermine viability if not addressed with regulatory and commercial endpoints in mind.
WHEN EARLY DECISIONS DEFINE THE DEVELOPMENT PATH
Choices around API definition, formulation, and clinical strategy made early will determine regulatory pathways, timelines, and cost. Decisions made without downstream alignment often lead to delays, rework, or misaligned development strategies.
WHEN PREPARING FOR HIGH-STAKES REGULATORY INTERACTION
FDA INTERACT meetings, pre-IND planning, and early regulatory engagement require clear positioning. How your program is framed at this stage influences feedback, expectations, and long-term development flexibility.
WHEN HIGH-STAKES DECISIONS REQUIRE INDEPENDENT CLARITY
Program continuation, investment diligence, and strategic pivots often involve scientific, technical, and regulatory uncertainty. Independent assessment ensures decisions are well-founded, defensible, and aligned before significant resources are committed.
GLOBAL EXPERIENCE
Regulatory strategy across global markets from API development through approval.
0
0
0
0
0
+
COUNTRIES
CONTINENTS
REGULATORY AUTHORITIES
+
CLIENTS SUPPORTED
YEARS ESTABLISHED
_edited.png)
VALUES
Grounded in science. Focused on people. Committed to integrity.
HUMAN-CENTERED SCIENCE
Scientific progress matters only if it improves real-world outcomes. Every solution is grounded in practical context and designed for measurable impact.
GLOBAL RESPONSIBILITY
Drug development spans diverse regulatory systems, cultures, and communities. Strategic decisions should account for their broader impact across these contexts.
OPERATIONAL INTEGRITY
Scientific and regulatory work demands rigor, clarity, and accountability. Trust is earned through transparent communication and decisions that withstand scrutiny.
